Want to see RNAC full AI Analyst Report?
RNAC Stock Chart & Stats
$10.38
-$0.09(-1.14%)
At close: 4:00 PM EDT
$10.38
-$0.09(-1.14%)
Day’s Range― - ―
52-Week Range$5.60 - $11.00
Previous Close$7.79
Volume79.05K
Average Volume (3M)136.90K
Market Cap
$189.70M
Enterprise Value$227.40M
Total Cash (Recent Filing)$147.61M
Total Debt (Recent Filing)$63.85M
Price to Earnings (P/E)―
Beta2.79
Next Earnings
Nov 05, 2026EPS Estimate
-1.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.93
Shares Outstanding30,255,352
10 Day Avg. Volume159,969
30 Day Avg. Volume136,899
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-1.48
Price to Sales (P/S)66.95
P/FCF Ratio-2.36
Enterprise Value/Market Cap1.20
Enterprise Value/Revenue153.96
Enterprise Value/Gross Profit-20.09
Enterprise Value/Ebitda-1.44
Forecast
1Y Price Target
$32.60Price Target Upside214.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-2.99
Revenue Forecast (FY)$422.29K
Bulls Say, Bears Say
Bulls Say
Transient MRNA Cell-therapy PlatformCartesian’s transient mRNA approach is designed to engineer therapeutic cells without permanent genetic modification. That differentiates its platform from permanently altered therapies and could support a repeatable development strategy across autoimmune diseases and selected cancers if clinical results continue to validate the mechanism.
Clinical Efficacy In Myasthenia GravisThe Phase 2 retreatment results provide evidence of clinically meaningful and durable symptom improvement in generalized myasthenia gravis. Sustained benefits over 12 months strengthen the therapeutic profile of Descartes-08 and support continued investment as the program moves toward later-stage testing.
Pipeline Advancement Toward Pivotal DevelopmentProgression toward Phase 3 AURORA topline data and a planned biologics license application represents a meaningful development milestone. Advancing the lead program into pivotal-stage evaluation could improve the company’s strategic position and create a clearer path toward eventual commercialization.
Bears Say
Severe Revenue ContractionThe sharp decline in revenue demonstrates a highly unstable top-line profile and limited current commercial contribution. With TTM revenue at only $1.5 million, Cartesian has little operating income to offset research spending, increasing dependence on financing while clinical programs remain in development.
Persistent Operating LossesA roughly $152 million TTM net loss and negative gross profit indicate that the current business model is not yet economically self-sustaining. Continued large losses can consume resources needed for clinical execution and reduce financial flexibility before any product achieves approval or recurring sales.
Ongoing Cash Burn And Funding DependenceSustained negative operating and free cash flow shows that Cartesian must fund ongoing development externally rather than through internally generated cash. The burn remains materially worse than 2024 and creates continuing financing needs, which can constrain investment choices and pressure the company’s long-term capital structure.
Cartesian Therapeutics News
RNAC FAQ
What was Cartesian Therapeutics’s price range in the past 12 months?
Cartesian Therapeutics lowest stock price was $5.60 and its highest was $11.00 in the past 12 months.
What is Cartesian Therapeutics’s market cap?
Cartesian Therapeutics’s market cap is $189.70M.
When is Cartesian Therapeutics’s upcoming earnings report date?
Cartesian Therapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 17 days.
How were Cartesian Therapeutics’s earnings last quarter?
Cartesian Therapeutics released its earnings results on Aug 06, 2026. The company reported $0.46 earnings per share for the quarter, beating the consensus estimate of -$0.878 by $1.338.
Is Cartesian Therapeutics overvalued?
According to Wall Street analysts Cartesian Therapeutics’s price is currently Undervalued.
Does Cartesian Therapeutics pay dividends?
Cartesian Therapeutics does not currently pay dividends.
What is Cartesian Therapeutics’s EPS estimate?
Cartesian Therapeutics’s EPS estimate is -1.01.
How many shares outstanding does Cartesian Therapeutics have?
Cartesian Therapeutics has 30,255,352 shares outstanding.
What happened to Cartesian Therapeutics’s price movement after its last earnings report?
Cartesian Therapeutics reported an EPS of $0.46 in its last earnings report, beating expectations of -$0.878. Following the earnings report the stock price went up 4.91%.
Which hedge fund is a major shareholder of Cartesian Therapeutics?
Currently, no hedge funds are holding shares in RNAC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cartesian Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$32.60 (214.07% Upside)
$32.60 (214.07% Upside)
Blogger Sentiment
Bullish
RNAC Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 22.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 2.0%
Last 30 Days ▲ 1.6%
Last 30 Days ▲ 1.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.43%
12-Months-Change
Fundamentals
Return on Equity
141.41%
Trailing 12-Months
Asset Growth
-18.07%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cartesian Therapeutics
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
RNAC Stock 12 Month Forecast
Average Price Target
$32.60
▲(214.07% Upside)
Technical Analysis
Ownership Overview
42.90% Insiders
7.11% Mutual Funds
<0.01% Other Institutional Investors
45.06% Public Companies and
Individual Investors